William Blair Lifts Earnings Estimates for Alto Neuroscience

Alto Neuroscience, Inc. (NYSE:ANRO) – Analysts at William Blair raised their FY2025 earnings estimates for Alto Neuroscience in a research report issued on Wednesday, November 12th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($2.14) for the year, up from their previous estimate of ($2.31). The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at ($3.07) EPS, FY2028 earnings at ($4.04) EPS and FY2029 earnings at ($2.32) EPS.

ANRO has been the topic of a number of other research reports. Jefferies Financial Group lifted their price objective on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. HC Wainwright lifted their price target on Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 24th. BTIG Research started coverage on shares of Alto Neuroscience in a research report on Monday. They set a “buy” rating and a $27.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. Finally, Chardan Capital began coverage on shares of Alto Neuroscience in a research note on Monday, September 29th. They set a “buy” rating and a $15.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus price target of $23.83.

Alto Neuroscience Trading Up 7.0%

Shares of Alto Neuroscience stock opened at $14.77 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The stock’s 50 day simple moving average is $8.13 and its 200-day simple moving average is $4.71. The stock has a market cap of $458.78 million, a P/E ratio of -6.45 and a beta of 2.90. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $15.18.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14.

Hedge Funds Weigh In On Alto Neuroscience

Large investors have recently made changes to their positions in the stock. Citizens Financial Group Inc. RI acquired a new stake in Alto Neuroscience in the 1st quarter valued at approximately $83,000. Invesco Ltd. purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at $67,000. Nuveen LLC purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at $302,000. Armistice Capital LLC boosted its holdings in Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock valued at $3,456,000 after acquiring an additional 950,000 shares during the period. Finally, AWM Investment Company Inc. boosted its holdings in Alto Neuroscience by 31.1% during the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after acquiring an additional 214,153 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.